John Bode Biography and Net Worth

Director of Zevra Therapeutics


John B. Bode has served as a director of our Company since April 2023, and as the chair of the nominating and corporate governance committee since May 2023. Since February 2015, Mr. Bode has been the owner and managing director of Aerie Investments, LLC, an investment company focused on assisting legacy media companies and digital media start-ups with business development, strategic initiatives, and raising capital. Mr. Bode currently serves as the chief financial officer and chief transformation officer of Postmedia Network Canada Corp., a publishing company whose shares are traded on the Toronto Stock Exchange.  Since September 2022, he has served as the interim chief executive officer of Fision Holdings, Inc. and previously served as an independent member of its board of directors from March 2018 to September 2022. Mr. Bode’s past corporate experience includes many years serving as a key executive and/or financial officer for leading public companies. Prior to the founding of Aerie Investments, LLC, Mr. Bode was the chief financial officer of the Tribune Publishing Company from October 2013 to January 2015. From January 2011 to September 2013, Mr. Bode served as the chief financial officer of Source Interlink Companies, one of the largest enthusiast media companies in the United States and a leading distributor of periodicals, after serving in other accounting and finance roles with Source Interlink since 2002. Mr. Bode currently serves as on the board of The McClatchy Company, a leading privately-held publisher of newspapers, as well as of SPAR Group, Inc., a leading global provider of merchandising, marketing and distribution services that is listed on the Nasdaq. He was previously employed as a certified public accountant for BDO Seidman. Mr. Bode received a BS in accounting from Notre Dame University.

What is John B. Bode's net worth?

The estimated net worth of John B. Bode is at least $389.70 thousand as of August 19th, 2025. Mr. Bode owns 45,000 shares of Zevra Therapeutics stock worth more than $389,700 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Bode may own. Learn More about John B. Bode's net worth.

How do I contact John B. Bode?

The corporate mailing address for Mr. Bode and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on John B. Bode's contact information.

Has John B. Bode been buying or selling shares of Zevra Therapeutics?

John B. Bode has not been actively trading shares of Zevra Therapeutics during the past quarter. Most recently, on Tuesday, August 19th, John B. Bode bought 5,000 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $9.16 per share, with a total value of $45,800.00. Following the completion of the transaction, the director now directly owns 45,000 shares of the company's stock, valued at $412,200. Learn More on John B. Bode's trading history.

Who are Zevra Therapeutics' active insiders?

Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Neil McFarlane (President & Chief Executive Officer), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.

Are insiders buying or selling shares of Zevra Therapeutics?

In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.

Information on this page was last updated on 10/10/2025.

John B. Bode Insider Trading History at Zevra Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2025Buy5,000$9.16$45,800.0045,000View SEC Filing Icon  
3/19/2025Buy10,000$7.96$79,600.0040,000View SEC Filing Icon  
7/12/2024Buy10,000$5.87$58,700.0030,000View SEC Filing Icon  
9/5/2023Buy10,000$5.13$51,300.0020,000View SEC Filing Icon  
5/18/2023Buy10,000$5.04$50,400.0010,000View SEC Filing Icon  
See Full Table

John B. Bode Buying and Selling Activity at Zevra Therapeutics

This chart shows John B Bode's buying and selling at Zevra Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zevra Therapeutics Company Overview

Zevra Therapeutics logo
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Read More

Today's Range

Now: $8.66
Low: $8.48
High: $8.80

50 Day Range

MA: $9.79
Low: $8.17
High: $11.78

2 Week Range

Now: $8.66
Low: $6.19
High: $13.16

Volume

823,188 shs

Average Volume

1,395,027 shs

Market Capitalization

$487.56 million

P/E Ratio

18.43

Dividend Yield

N/A

Beta

1.01